Featured Stock

LASD

Lasco Distributors Limited (LASD);

Opening price— $3.57;

Price to book— 1.09 times;

P/E— 10.49 times

Week to Date:	19.43%
Month to Date:	19.43%
Quarter to Date:	19.47%
Year to Date:	5.13%

Our weekly pick features a stock currently held in the Mayberry Managed Equity Portfolio (MMEP). For more information on the MMEP, please contact your investment advisor today.

LASCO Distributors Limited (LASD) is a leading Jamaican distributor of consumer, pharmaceutical, food, beverage, personal care, and household products. Through its broad portfolio of LASCO-branded and third-party products, extensive distribution network, and growing healthcare and export operations, the company continues to focus on expanding market reach, strengthening customer engagement, and improving supply-chain efficiency.

For the three months ended 30 June 2026, LASD delivered a strong start to the financial year, with revenue increasing by 16.1% to J$8.44 billion, compared with J$7.27 billion in the prior-year period. Growth was supported by strong performances across the Nutrition, Food & Beverage categories, alongside improved results in Home Care, Personal Care, and Healthcare. Management attributed the performance to continued demand-generation initiatives, stronger distribution execution, and improved product availability.

Gross profit increased by 22.4% to J$1.54 billion, outpacing revenue growth, while gross margin improved to approximately 18.3% from 17.4% in the prior year. The improvement reflected strategic price adjustments across selected categories in response to higher supplier costs, together with strong consumer demand and improved performance across key food and beverage products.

Operating expenses increased by 8.3% to J$1.06 billion as the company continued investing in sales execution, brand development, and marketing initiatives. However, expense growth remained well below the increase in revenue and gross profit, resulting in operating profit rising by 48.6% to J$538.2 million. Finance costs increased to J$16.3 million from J$7.8 million, reflecting additional borrowing associated with continued investment in the company's warehouse expansion project.

Despite the higher finance costs, profit before taxation increased by 47.3% to J$521.9 million, while net profit rose by 45.4% to J$441.9 million from J$303.9 million in the prior-year quarter. Earnings per stock unit improved to J$0.13 from J$0.09, demonstrating LASD's ability to translate strong top-line growth and improved margins into meaningful earnings expansion.

Strategically, LASD continues to pursue growth through stronger distribution capabilities, category expansion, and deeper market penetration. Management highlighted continued momentum in its export business, supported by stronger relationships with distribution partners and improved market execution. The Healthcare division also remains an important growth area, benefiting from improved management across key therapeutic categories, enhanced product availability, and the continued expansion of the company's pharmaceutical portfolio.

The company is also investing in its warehouse expansion project to strengthen supply-chain capacity and support future growth. Alongside continued investment in sales, marketing, and customer engagement, the expanded infrastructure is expected to improve operational capacity and position LASD to capture additional opportunities across its domestic and export markets.

LASD (as at Friday June 7th, 2026) was trading at 1.09 times its book value with a P/E of 10.49 times.